ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0420

Associations and Mortality Impact of Machine Learning-derived Quantitative Computed Tomography Parenchymal Lung Features in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort of Smokers

Gregory McDermott1, Keigo Hayashi1, Matthew Moll1, Michael Cho1, Kazuki Yoshida1, Tracy J. Doyle1, Gregory Kinney2, Paul Dellaripa3, Zachary Wallace4, Elizabeth Regan5, Gary Hunninghake1, Edwin Silverman1, Samuel Ash1, Raul San Jose Estepar1, George Washko1 and Jeffrey Sparks6, 1Brigham and Women's Hospital, Boston, MA, 2University of Colorado Denver, Denver, CO, 3Brigham and Women's Hospital, Boston, MA, 4Massachusetts General Hospital, Newton, MA, 5National Jewish Health, Denver, CO, 6Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2023

Keywords: Computed tomography (CT), interstitial lung disease, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Quantitative computed tomography (QCT) methods have been developed to automatically quantify parenchymal lung features on chest CT imaging. There have been limited investigations of QCT in RA participants and non-RA comparators or studies of the mortality impact of QCT features in RA. We hypothesized that RA would be associated with increased interstitial changes and emphysema, as determined by QCT. We also hypothesized that QCT scoring of interstitial and emphysematous lung changes would identify RA patients at higher mortality risk.

Methods: We investigated associations between RA and QCT features in COPDGene, a multicenter cohort study of current or former smokers that excluded participants with known interstitial lung disease or bronchiectasis. We identified participants with and without RA using RA self-report and DMARD use. We assessed the lung parenchyma in each scan using a k-nearest neighbors classifier that categorizes regions of interest into normal lung, interstitial changes, or emphysema using the local tissue density and distance from the pleural surface. Interstitial changes were subclassified into reticular, subpleural line, linear scar, honeycombing, centrilobular nodule, nodular, and ground glass. Each feature was summed and standardized to total lung volume. We examined associations between QCT features and RA using multivariable linear regression. We dichotomized participants using the 75th percentile for each QCT feature among non-RA participants and investigated mortality associations by RA status and QCT features using Cox regression. We examined multiplicative interactions between RA and continuous interstitial and emphysema percentages and additive interactions between RA status and >75th percentile of QCT features and mortality.

Results: We analyzed 82 RA cases and 8820 non-RA comparators. RA was associated with a lower percentage of normal lung (85.8% vs. 91.0% p=0.0001), increased interstitial changes (7.0% vs. 4.8%, p< 0.0001) and no statistically significant difference in emphysema (2.6% vs. 1.9%, p=0.09) compared to non-RA comparators. In linear regression analyses adjusted for age, sex, smoking status, pack-years, and body mass index, RA was associated with increased interstitial changes (β=1.7±0.5, p=0.0008) but not emphysema (β=1.3±1.7, p=0.44). The combination of RA and >75th percentile of emphysema had significantly higher mortality compared to both non-RA participants (HR 5.86, 95%CI 3.75-9.13) and RA participants (HR 5.56, 95%CI 2.71-11.38) with < 75th percentile of emphysema. There were statistically significant interactions between RA and emphysema for mortality (multiplicative: p=0.014; additive: attributable proportion 0.53, 95%CI 0.30-0.70, p< 0.0001).

Conclusion: Using machine learning-derived QCT data in a cohort of smokers, we found that RA was associated with increased interstitial changes, even after adjustment for smoking and other lifestyle factors. The combination of RA and emphysema conferred greater than 5-fold increased mortality.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: G. McDermott: None; K. Hayashi: None; M. Moll: Bayer, 5; M. Cho: AstraZeneca, 2, Bayer, 5, GSK, 5, Illumina, 6; K. Yoshida: None; T. Doyle: None; G. Kinney: None; P. Dellaripa: None; Z. Wallace: BioCryst, 2, Bristol-Myers Squibb(BMS), 5, Horizon, 1, 2, 5, MedPace, 2, Novartis, 1, PPD, 2, Sanofi, 1, 5, Shionogi, 1, Visterra, 1, 2, Zenas, 1, 2; E. Regan: None; G. Hunninghake: Boehringer-Ingelheim, 2, Chugai Pharamaceuticals, 2, Gerson Lehrman Group, 2; E. Silverman: Bayer, 5; S. Ash: Boehringer-Ingelheim, 5, Quantitative Imaging Solutions, 8, 10, Verona Pharmaceuticals, 1; R. San Jose Estepar: Boehringer-Ingelheim, 5, Chiesi, 6, Imbio, 9, Insmed, 5, Leuko Labs, 2, Lung Biotechnology, 5; G. Washko: Boehringer-Ingelheim, 5, Janssen, 2, Novartis, 2, Pulmonx, 2, Quantitative Imaging Solutions, 8, Vertex, 2; J. Sparks: AbbVie, 2, Amgen, 2, Boehringer Ingelheim, 2, Bristol-Myers Squibb, 2, 5, Gilead, 2, Inova Diagnostics, 2, Janssen, 2, Optum, 2, Pfizer, 2, ReCor, 2.

To cite this abstract in AMA style:

McDermott G, Hayashi K, Moll M, Cho M, Yoshida K, Doyle T, Kinney G, Dellaripa P, Wallace Z, Regan E, Hunninghake G, Silverman E, Ash S, San Jose Estepar R, Washko G, Sparks J. Associations and Mortality Impact of Machine Learning-derived Quantitative Computed Tomography Parenchymal Lung Features in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort of Smokers [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/associations-and-mortality-impact-of-machine-learning-derived-quantitative-computed-tomography-parenchymal-lung-features-in-rheumatoid-arthritis-and-non-ra-comparators-in-a-multicenter-prospective-coh/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-and-mortality-impact-of-machine-learning-derived-quantitative-computed-tomography-parenchymal-lung-features-in-rheumatoid-arthritis-and-non-ra-comparators-in-a-multicenter-prospective-coh/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology